Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine

Attention-deficit/Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type (Stimulants (Amphetamine, Methylphenidate, Dextroamphetamine, Dexmethylphenidate, Lisdexamfetamine Dimesylate), Non-stimulants (Atomoxetine, Bupropion, Guanfacine, Clonidine)), By Age Group (Pediatric and Adolescent, Adults), By Distribution Channel (Specialty Clinics, Hospital Pharmacies, Retail Pharmacies, e-Commerce), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Attention deficit hyperactivity disorder (ADHD) is a neural disorder. The disorder is characterized by impulsiveness, hyperactivity, and attention difficulty. Treatment of ADHD involves a combination of counseling, medications, and lifestyle changes. ADHD is the most commonly diagnosed mental disorder in adults and children with the exact cause being unidentified in the majority of cases. Researchers at the National Institute of Mental Health (NIMH) suggest the factors affecting mental illness include heredity, brain injuries, low birth weight, drugs use during pregnancy and exposure to environmental toxins such, as lead at young age. The currently available treatments, such as medication, counseling, lifestyle changes or a combination of these treatments helps in reducing symptoms with improved functioning of patient.

Restraints of the Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market

Major factors hampering the growth of the attention-deficit hyperactivity disorder (ADHD) therapeutics market during the forecast period constitutes of side effects, and drug abuse risks.

Key features of the study:

  • This report provides in-depth analysis of the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals, Inc., RespireRx Pharmaceuticals Inc., Otsuka Pharmaceutical Co., Ltd., American BriVision (Holding) Corporation, Novartis Pharmaceuticals Corporation, Shire, GlaxoSmithKline, Celltech Group Ltd., and Purdue Pharma L.P.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type:
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Age Group:
  • Pediatric and Adolescent
  • Adults
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Distribution Channel:
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Geography:
  • North America
  • By Drug Type
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • By Age Group
  • Pediatric and Adolescent
  • Adults
  • By Distribution Channel
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • U.S.
  • Canada
  • Europe
  • By Drug Type
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • By Age Group
  • Pediatric and Adolescent
  • Adults
  • By Distribution Channel
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Type
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • By Age Group
  • Pediatric and Adolescent
  • Adults
  • By Distribution Channel
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • By Drug Type
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • By Age Group
  • Pediatric and Adolescent
  • Adults
  • By Distribution Channel
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East:
  • By Drug Type
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • By Age Group
  • Pediatric and Adolescent
  • Adults
  • By Distribution Channel
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Type
  • Stimulants
  • Amphetamine
  • Methylphenidate
  • Dextroamphetamine
  • Dexmethylphenidate
  • Lisdexamfetamine Dimesylate
  • Non-stimulants
  • Atomoxetine
  • Bupropion
  • Guanfacine
  • Clonidine
  • By Age Group
  • Pediatric and Adolescent
  • Adults
  • By Distribution Channel
  • Specialty Clinics
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Amedra Pharmaceuticals LLC*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Eli Lilly and Company
  • Janssen Pharmaceuticals, Inc.
  • Noven Pharmaceuticals, Inc.
  • RespireRx Pharmaceuticals Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • American BriVision (Holding) Corporation
  • Novartis Pharmaceuticals Corporation
  • Shire Plc
  • GlaxoSmithKline
  • Celltech Group Ltd.
  • Purdue Pharma L.P.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
• Market Definition and Scope
Executive Summary
• Market Snippet, By Drug Type
• Market Snippet, By Age Group
• Market Snippet, By Distribution Channel
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
• Drivers
• Restraints
• Market Opportunities
Impact Analysis
Key Developments
Regulatory Scenario
PEST Analysis
COVID-19 Impact Analysis
4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Drug Type, 2019 – 2027 (US$ Mn)
Introduction
• Market Share Analysis, 2019 and 2027 (%)
• Y-o-Y Growth Analysis, 2017–2027
• Segment Trends
Stimulants
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
• Segment Trends
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
• Segment Trends
Atomoxetine
Bupropion
Guanfacine
Clonidine
5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Age Group, 2019 – 2027 (US$ Mn)
Introduction
• Market Share Analysis, 2019 and 2027 (%)
• Y-o-Y Growth Analysis, 2017–2027
• Segment Trends
Pediatric and Adolescent
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Adults
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
Introduction
• Market Share Analysis, 2019 and 2027 (%)
• Y-o-Y Growth Analysis, 2017–2027
• Segment Trends
Specialty Clinics
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Hospital Pharmacies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Retail Pharmacies
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
e-Commerce
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
7. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market, By Regions, 2019 – 2027 (US$ Mn)
Introduction
• Market Share Analysis, 2019 and 2027 (%)
• Y-o-Y Growth Analysis, 2017–2027
• Segment Trends
North America
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
U.S.
Canada
Europe
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
• Introduction
• Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
North Africa
Central Africa
South Africa
8. Competitive Landscape
Company Profiles
• Amedra Pharmaceuticals LLC
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Eli Lilly and Company
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Janssen Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Noven Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• RespireRx Pharmaceuticals Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Otsuka Pharmaceutical Co., Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• American BriVision (Holding) Corporation
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Novartis Pharmaceuticals Corporation
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Shire Plc
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• GlaxoSmithKline
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Celltech Group Ltd.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
• Purdue Pharma L.P.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 34 market data tables and 24 figures on “Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market – Global forecast to 2027.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook